# Phase 2 melanoma trials recruiting: 97 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 97 trials in phase 2 for melanoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 melanoma trials: 97 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/melanoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 97
- Recruiting or not yet: 97
- Read on: November 19, 2026

## Trials

The 25 newest of 97, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07934927 | A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Mucosal Melanoma | Sun Yat-sen University | Phase 2 | Recruiting | Melanoma, Immune Checkpoint Inhibitor | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934927) |
| November 10, 2026 | NCT07930182 | Adjuvant/Neoadjuvant Immunotherapy in Melanoma Based on Serial Plasma ctDNA Monitoring | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | Recruiting | Melanoma | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930182) |
| October 23, 2026 | NCT07891286 | Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | LGCMN, Large and Giant Congenital Melanocytic Nevi, NF1, Solid Tumor, Pediatric Tumors, Neurocutaneous Melanocytosis... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891286) |
| October 20, 2026 | NCT07883759 | Neoadjuvant Pembrolizumab in Patients With High Risk, Stage IIB/IIC Cutaneous Melanoma: a Single Arm Proof of Concept Phase IIA Study. | Centre Hospitalier Universitaire de Besancon | Phase 2 | Not yet recruiting | Stage IIB Melanoma, Stage IIC Melanoma | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883759) |
| October 7, 2026 | NCT07862530 | Neoadjuvant RP2 + Nivolumab in Patients With Melanoma | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | MelanomaCutaneous Melanoma Resectable, Melanoma | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862530) |
| September 29, 2026 | NCT07848243 | Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes | Peking University Cancer Hospital & Institute | Phase 2 | Recruiting | Lung Cancer (NSCLC), Cervical Squamous Cell Cancer, Melanoma (Skin Cancer), Breast Cancer, Gastrointestinal Cancers | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848243) |
| September 29, 2026 | NCT07847359 | Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib... | Sun Yat-sen University | Phase 2 | Recruiting | Melanoma (Skin) Stage IV | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847359) |
| September 23, 2026 | NCT07836712 | Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced... | University of Southern California | Phase 2 | Not yet recruiting | Advanced Hepatocellular Carcinoma, Advanced Melanoma, Locally Advanced Melanoma, Metastatic Melanoma, Stage III... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836712) |
| September 15, 2026 | NCT07820033 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial | University Health Network, Toronto | Phase 2 | Not yet recruiting | Advanced Cancer, Stage IV Solid Tumor Cancer, Stage IV Sarcoma of Bone, Stage IV Lymphoma, Stage IV Melanoma, Endocrine... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07820033) |
| September 8, 2026 | NCT07807878 | Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma | Assistance Publique Hopitaux De Marseille | Phase 2 | Not yet recruiting | Cutaneous Melanoma | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807878) |
| August 6, 2026 | NCT07750067 | Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma | Sun Yat-sen University | Phase 2 | Recruiting | Melanoma Metastatic, NRAS Mutation | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07750067) |
| August 3, 2026 | NCT07740941 | NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma | UNC Lineberger Comprehensive Cancer Center | Phase 2 | Recruiting | Melanoma (Skin Cancer), Melanoma Stage Stage IIIB, Melanoma Stage M1, Melanoma Stage IV | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07740941) |
| July 7, 2026 | NCT07686835 | Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma. | Radboud University Medical Center | Phase 2 | Recruiting | Melanoma (Skin) Stage IV, Melanoma (Skin Cancer), Melanoma Metastatic, Melanoma Advanced, Melanoma | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686835) |
| June 16, 2026 | NCT07651618 | A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant... | East Metropolitan Health Service, Australia | Phase 2 | Not yet recruiting | Melanoma (Skin Cancer), Melanoma Metastatic | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07651618) |
| June 12, 2026 | NCT07644897 | Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma | Sun Yat-sen University | Phase 2 | Recruiting | Melanoma, Immune-related Adverse Event, Immune Checkpoint Inhibitor | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07644897) |
| June 2, 2026 | NCT07621614 | A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information | Children's Oncology Group | Phase 2 | Recruiting | Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous... | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07621614) |
| June 2, 2026 | NCT07619898 | PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to... | Therakos LLC | Phase 2 | Not yet recruiting | Colitis, Hepatitis, Melanoma (Skin Cancer) | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619898) |
| May 8, 2026 | NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07576725) |
| May 7, 2026 | NCT07574047 | MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. | Swiss Cancer Institute | Phase 2 | Recruiting | Melanoma, Advanced Melanoma | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07574047) |
| May 4, 2026 | NCT07565285 | The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma | Primmune Therapeutics, Inc. | Phase 2 | Recruiting | Melanoma Stage III | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07565285) |
| April 14, 2026 | NCT07527325 | Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma | University of California, Irvine | Phase 2 | Not yet recruiting | Melanoma (Skin) | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527325) |
| April 8, 2026 | NCT07517653 | Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Melanoma | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517653) |
| April 6, 2026 | NCT07511036 | PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically... | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Melanoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07511036) |
| April 1, 2026 | NCT07504796 | ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab | NYU Langone Health | Phase 2 | Recruiting | Metastatic Melanoma, Advanced Melanoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07504796) |
| March 30, 2026 | NCT07501104 | Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Melanoma (Skin Cancer) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07501104) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 6 |
| Sun Yat-sen University | 4 |
| H. Lee Moffitt Cancer Center and Research Institute | 4 |
| National Cancer Institute (NCI) | 4 |
| University of California, Irvine | 3 |
| UNICANCER | 2 |
| Mayo Clinic | 2 |
| Peking University Cancer Hospital & Institute | 2 |
| Grupo Español Multidisciplinar de Melanoma | 2 |
| University Health Network, Toronto | 2 |
| Shanghai Zhongshan Hospital | 2 |
| [Innovent Biologics (Suzhou) Co. Ltd.](https://specstream.ai/data/clinical-trials/company/innovent-biologics-suzhou-co-ltd) | 2 |
| Melanoma Institute Australia | 2 |
| University of Miami | 2 |
| NYU Langone Health | 2 |
| Primmune Therapeutics, Inc. | 1 |
| Oslo University Hospital | 1 |
| Maria Sklodowska-Curie National Research Institute of Oncology | 1 |
| Brigham and Women's Hospital | 1 |
| The First People's Hospital of Changzhou | 1 |
| University of California, San Francisco | 1 |
| Stanford University | 1 |
| Rapa Therapeutics LLC | 1 |
| University Medical Center Groningen | 1 |
| City of Hope Medical Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 48 |
| China | 16 |
| Australia | 8 |
| France | 6 |
| Spain | 6 |
| Canada | 5 |
| Germany | 5 |
| Norway | 4 |
| Netherlands | 4 |
| Belgium | 3 |
| Italy | 3 |
| South Korea | 3 |
| Denmark | 3 |
| Japan | 2 |
| Taiwan | 2 |
| United Kingdom | 2 |
| Switzerland | 2 |
| Hong Kong | 1 |
| Ireland | 1 |
| Sweden | 1 |
| Uganda | 1 |
| Russia | 1 |
| Hungary | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Orthotics providers in the United States](https://specstream.ai/data/businesses/orthotics-providers/united-states)
- [Dialysis clinics in the United States](https://specstream.ai/data/businesses/dialysis-clinics/united-states)
- [Tenant and eviction law firms in the United States](https://specstream.ai/data/businesses/tenant-and-eviction-law-firms/united-states)
- [International fusion restaurants in the United States](https://specstream.ai/data/businesses/international-fusion-restaurants/united-states)
- [Bed and breakfasts in the United States](https://specstream.ai/data/businesses/bed-and-breakfasts/united-states)
- [Private jet charter companies in the United States](https://specstream.ai/data/businesses/private-jet-charter-companies/united-states)
